Results 141 to 150 of about 6,725 (159)

Determination of the Absolute Oral Bioavailability of Niraparib by Simultaneous Administration of a 14C-Microtracer and Therapeutic Dose in Cancer Patients

Cancer Chemotherapy and Pharmacology, 2018
Lotte van Andel, Jos Beijnen, M M Tibben
exaly  

Niraparib/romiplostim

Reactions Weekly, 2023
openaire   +1 more source

Dostarlimab/niraparib

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and Safety of Niraparib as Maintenance Treatment in Older Patients (≥ 70 Years) With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial

Gynecologic Oncology, 2019
Ronnie Shapira-Frommer, Sven Mahner, Kristina Hellman   +2 more
exaly  

A Pan-Tumor Review of the Role of Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors

Ca-A Cancer Journal for Clinicians
Jennifer K Litton, Nicolas Sayegh, Chadi Hage Chehade   +2 more
exaly  

Niraparib for the Treatment of Ovarian Cancer

Expert Review of Anticancer Therapy, 2018
Kathleen N. Moore, Kathleen G Essel
exaly  

Dostarlimab and Niraparib in Primary Advanced Ovarian Cancer

Annals of Oncology
T-E Ciuleanu, R Eitan, M R Mírzá
exaly  

Synthesis of Niraparib

Synfacts, 2014
openaire   +1 more source

Niraparib/olaparib

Reactions Weekly
  +5 more sources

Niraparib First-Line Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: Final Overall Survival Results From the PRIMA/ENGOT-ov26/GOG-3012 Trial☆

Annals of Oncology
L L Holman, R E O'Cearbhaill, I Bruchim
exaly